Drug Profile
Research programme: beta-thalassaemia gene therapy - Avigen
Alternative Names: Beta-thalassaemia gene therapy with erythropoietin - AvigenLatest Information Update: 07 Sep 2005
Price :
$50
*
At a glance
- Originator Avigen
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thalassaemia
Most Recent Events
- 27 Jun 2005 Discontinued - Preclinical for Thalassaemia in USA (unspecified route)
- 19 Mar 2003 Suspended - Preclinical for Thalassaemia in USA (unspecified route)
- 09 Jul 2001 This programme is still in active development